Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 42 |
| Active Pipeline (Recruiting Now) | 21 (12) |
| Completed vs Stopped Early | 9 / 7 (16.7%) |
| Median Closed Actual Enrollment | 40 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Centre Léon Bérard | Lyon | 30 |
| Institut Gustave Roussy | Villejuif | 17 |
| Centre Antoine-Lacassagne | Nice | 15 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06692556 | Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Centre Leon Berard Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.